

RESPONDER CELLS: RAT SPLEEN CELLS
STIMULATOR CELLS: HUMAN HEPATOCYTES

SPLEEN(S): SPLEEN CELLS FROM RATS
TREATED WITH SALINE WHEN THEY WERE
FETUSES.

HEP: IRRADIATED HUMAN HEPATOCYTES.


SPLEEN(IU): SPLEEN CELLS FROM RATS
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES.

SPLEEN(IU/IS): SPLEEN CELLS FROM RAT
TOLERIZED BY INTRAUTERINE INJECTION OF
HUMAN HEPATOCYTE LYSATES FOLLOWED
BY INTRASPLenic TRANSPLANTATION OF
HUMAN HEPATOCYTES AFTER BIRTH.

FIG.1

1 2 3 4 5

FIG. 2



- 1: Molecular weight markers
- 2: Human serum albumin, 50 ug
- 3: Human serum albumin, 10 ug
- 4: Human serum albumin, 1 ug
- 5: Week 1 post-human hepatocyte transplant
- 6: Week 2 post-human hepatocyte transplant
- 7: Week 3 post-human hepatocyte transplant
- 8: Week 4 post-human hepatocyte transplant
- 9: Week 5 post-human hepatocyte transplant
- 10: Control animal. human fibroblast transplant. 1 week
- 11: Rat serum albumin, 50 ug

FIG 3



FIG. 4A




FIG. 4B




FIG. 4C



FIG. 4D




FIG.5



FIG. 6A




FIG. 6B



FIG. 6C



FIG. 6D




FIG.7

Time course of human albumin and HBV expression

Anti Human Albumin

Anti Hepatitis B Surface Antigen

1 week




FIG. 8A




FIG. 8B

6 weeks




FIG. 8C



FIG. 8D

A dark, high-contrast, black and white photograph of a textured surface, possibly a book cover or endpaper. The image is mostly black with some visible grain and texture. Along the right edge, there is a vertical strip of lighter, more detailed texture, showing what appears to be the binding or a hinge of a book. There are some small, light-colored specks and fibers visible in this area. The overall appearance is that of a very dark, possibly damaged or aged, surface.

FIG. 8F

FIG.9C

FIG. 9D

FIG.9C

10 μm

FIG. 9D

[illegible]

Rat CA5
HBV alone



FIG.9E



FIG.9F

Rat CA2
minus primary Ab




FIG.9G





FIG.9H

RT-PCR Human Albumin mRNA



- 1: 1000 bp ladder
- 2: Rat RNA
- 3: Human RNA
- 4: HepG2.2.15 RNA
- 5: Rat CA1 - Human hepatocytes + HBV
- 6: Rat CA2 - Human hepatocytes + HBV
- 7: Rat CA3 - Human hepatocytes
- 8: Rat CA4 - Human hepatocytes
- 9: Rat CA5 - HBV
- 10: Rat CA6 - HBV
- 11: Rat CA7 - Saline

FIG 10

RT-PCR Human Albumin RNA

1 2 3 4 5 6 7





FIG 11A

RT-PCR HBV RNA

1 2 3 4 5 6 7



- 1: 1 kbp ladder
- 2: Rat liver RNA
- 3: Human liver RNA
- 4: HepG2.2.14 RNA
- 5: Rat CA2 - Human hepatocytes +HBV, 1 week post
- 6: Rat CA2 - 6 weeks post
- 7: Rat CA2 - 14 weeks post

FIG 11B




FIG.12

Hepatocytes
plus HBV

1 week




FIG.13A

Hepatocytes
plus HBV

6 weeks




FIG.13B

Hepatocytes
plus HBV

14 weeks




FIG.13C

09930784-081504
F05T80 F84DCE60

Hepatocytes
plus HBV

1 week




FIG.14A

Hepatocytes
plus HBV

6 weeks




FIG.14B

Hepatocytes
plus HBV

14 weeks




FIG.14C

133430-134055




FIG. 15



FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG.17A




FIG.17B




FIG.17C




FIG.17D




FIG.18A




FIG.18B




FIG.19A




FIG.19B

The graph displays the concentration of serum HBsAg in pg/ml on the y-axis (0.0 to 1.0) against time in days post-inoculation on the x-axis (0 to 70). The solid line with circles represents the mean HBsAg levels, which show a peak around day 23 and then a gradual decline. The dashed line with squares represents the control group, which remains at 0.0 pg/ml throughout the 70-day period. Error bars are included for the mean data points.

Time Post-Inoculation (Days)	Mean Serum HBsAg (pg/ml)	Control Serum HBsAg (pg/ml)
0	0.00	0.00
3	0.20	0.00
5	0.10	0.00
10	0.50	0.00
15	0.33	0.00
18	0.36	0.00
23	0.72	0.00
40	0.56	0.00
60	0.62	0.00

FIG.20




Fig. 21




FIG. 22

CONFIDENTIAL FEB 20 2000

Day 1




FIG. 23A



FIG. 23B

X125

X250




FIG. 23C




FIG. 23D

X125

X250

Day 7




FIG. 23E



FIG. 23F

X125

X250

FIG. 24A




FIG. 24B




FIG. 24C




FIG. 24D








FIG. 25







FIG. 27B

FIG. 27A






FIG. 28

Human Albumin



FIG. 29A

BrdU



FIG. 29B

Tolerized
with T3
no trans-
plantation



FIG. 29C




FIG. 29D

Tolerized
with T3
and trans-
plantation



FIG. 29E




FIG. 29F

Control
no T3
no trans-
plantation

09930781.081501




FIG. 30

Time Post-HCV Inoculation (weeks)

16


12

8


6

4


2




+



+




+



+



+



+

Huh7


FIG. 31



-



-



+

HepG2



-



-



-



+



+

PHH



-



-



-



-



+

PBS

FIG. 32

Time Post-HCV Inoculation (weeks)

16


12

8


6

4

Huh7




+



+



+



+

HepG2



+

PHH



-



-



+

PBS